240 related articles for article (PubMed ID: 16784972)
1. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia.
Dayspring T; Qu Y; Keech C
Metabolism; 2006 Jul; 55(7):972-9. PubMed ID: 16784972
[TBL] [Abstract][Full Text] [Related]
2. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
Insull W; Davidson MH; Kulkarni PM; Siddhanti S; Ciaccia AV; Keech CA
Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
5. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
7. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Teerlink T; van der Mooren MJ
Fertil Steril; 2004 Dec; 82(6):1540-9. PubMed ID: 15589857
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.
Matsumura M; Monden T; Nakatani Y; Shimizu H; Domeki N; Yanagi K; Ikeda S; Kawagoe Y; Kasai K
Med Princ Pract; 2010; 19(1):68-72. PubMed ID: 19996623
[TBL] [Abstract][Full Text] [Related]
9. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
[TBL] [Abstract][Full Text] [Related]
10. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
[TBL] [Abstract][Full Text] [Related]
12. Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial.
Vigna GB; Pansini F; Bonaccorsi G; Albertazzi P; Donegà P; Zanotti L; De Aloysio D; Mollica G; Fellin R
Nutr Metab Cardiovasc Dis; 2000 Dec; 10(6):315-22. PubMed ID: 11302006
[TBL] [Abstract][Full Text] [Related]
13. Lipid and lipoprotein profile in physiological pregnancy.
Lippi G; Albiero A; Montagnana M; Salvagno GL; Scevarolli S; Franchi M; Guidi GC
Clin Lab; 2007; 53(3-4):173-7. PubMed ID: 17447654
[TBL] [Abstract][Full Text] [Related]
14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
Piperi C; Kalofoutis C; Skenderi K; Economidou O; Kalofoutis A
J Obstet Gynaecol; 2004 Jun; 24(4):414-9. PubMed ID: 15203583
[TBL] [Abstract][Full Text] [Related]
16. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
17. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
18. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.
Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P
Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536
[TBL] [Abstract][Full Text] [Related]
19. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Gol M; Baris N; Guneri S; Posaci C
Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene on lowering lipid parameters in patients with osteoporosis.
Miskić B; Bistrović D; Cosić V; Leko N; Balen-Jandrić M; Balen I; Samardzić P; Miskić D
Int J Clin Pharmacol Res; 2003; 23(4):107-10. PubMed ID: 15224499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
